Share Option Exercise and Issue of Equity
Updated : 14:29
2 December 2019
Diurnal Group plc
("Diurnal" or the "Company")
Share Option Exercise and Issue of Equity
Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces that it has issued 30,000 new ordinary shares of 5 pence each ("New Ordinary Shares") as a result of an exercise of options under the Company's Long Term Incentive Plan ("LTIP").
Application has been made for admission of the 30,000 New Ordinary Shares to trading on AIM, which is anticipated to occur at 8:00am on 6 December 2019 ("Admission"). The New Ordinary Shares will rank pari passu with the existing shares of common stock of the Company. Following Admission, the Company's issued ordinary share capital will consist of 86,535,440 ordinary shares. The Company does not hold any shares in treasury. Therefore, the total number of ordinary shares with voting rights in Diurnal following Admission will be 86,535,440.
The above figure of 86,535,440 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.
For further information, please visit www.diurnal.co.uk or contact: | |
Diurnal Group plc | +44 (0)20 3727 1000 |
Martin Whitaker, Chief Executive Officer | |
Richard Bungay, Chief Financial Officer | |
Panmure Gordon (UK) Limited (Nominated Adviser and Joint Broker) | +44 (0) 20 7886 2500 |
Corporate Finance: Freddy Crossley, Emma Earl | |
Corporate Broking: James Stearns | |
Cantor Fitzgerald Europe (Joint Broker) | +44 (0)20 7894 7000 |
Corporate Finance: Phil Davies, Will Goode, Michael Boot | |
Healthcare Equity Sales: Andrew Keith | |
FTI Consulting (Media and Investor Relations) | +44 (0)20 3727 1000 |
Simon Conway | |
Victoria Foster Mitchell | |
Notes to Editors
About Diurnal Group plc
Founded in 2004, Diurnal is a UK-based specialty pharma company developing high quality products for the global market for the life-long treatment of chronic endocrine conditions, including Congenital Adrenal Hyperplasia and Adrenal Insufficiency. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.
For further information about Diurnal, please visit www.diurnal.co.uk
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.